Inhibition of DNA Repair Enzymes as a Valuable Pharmaceutical Approach
Funding
Conflicts of Interest
References
- Lodovichi, S.; Cervelli, T.; Pellicioli, A.; Galli, A. Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach. Int. J. Mol. Sci. 2020, 21, 6684. [Google Scholar] [CrossRef] [PubMed]
- Sukhanova, M.V.; Singatulina, A.S.; Pastré, D.; Lavrik, O.I. Fused in Sarcoma (FUS) in DNA Repair: Tango with Poly(ADP-ribose) Polymerase 1 and Compartmentalisation of Damaged DNA. Int. J. Mol. Sci. 2020, 21, 7020. [Google Scholar] [CrossRef] [PubMed]
- Moor, N.; Vasil’eva, I.; Lavrik, O. Functional Role of N-Terminal Extension of Human AP Endonuclease 1 In Coordination of Base Excision DNA Repair via Protein–Protein Interactions. Int. J. Mol. Sci. 2020, 21, 3122. [Google Scholar] [CrossRef] [PubMed]
- Maluchenko, N.V.; Feofanov, A.V.; Studitsky, V.M. PARP-1-Associated Pathological Processes: Inhibition by Natural Polyphenols. Int. J. Mol. Sci. 2021, 22, 11441. [Google Scholar] [CrossRef] [PubMed]
- Nilov, D.; Maluchenko, N.; Kurgina, T.; Pushkarev, S.; Lys, A.; Kutuzov, M.; Gerasimova, N.; Feofanov, A.; Švedas, V.; Lavrik, O.; et al. Molecular Mechanisms of PARP-1 Inhibitor 7-Methylguanine. Int. J. Mol. Sci. 2020, 21, 2159. [Google Scholar] [CrossRef] [PubMed]
- Sherstyuk, Y.V.; Ivanisenko, N.V.; Zakharenko, A.L.; Sukhanova, M.V.; Peshkov, R.Y.; Eltsov, I.V.; Kutuzov, M.M.; Kurgina, T.A.; Belousova, E.A.; Ivanisenko, V.A.; et al. Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3. Int. J. Mol. Sci. 2020, 21, 214. [Google Scholar] [CrossRef] [PubMed]
- Ryu, H.; Kim, H.J.; Song, J.-Y.; Hwang, S.-G.; Kim, J.-S.; Kim, J.; Bui, T.H.N.; Choi, H.-K.; Ahn, J. A Small Compound KJ-28d Enhances the Sensitivity of Non-Small Cell Lung Cancer to Radio- and Chemotherapy. Int. J. Mol. Sci. 2019, 20, 6026. [Google Scholar] [CrossRef] [PubMed]
- Perini, V.; Schacke, M.; Liddle, P.; Vilchez-Larrea, S.; Keszenman, D.J.; Lafon-Hughes, L. PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors. Int. J. Mol. Sci. 2020, 21, 8288. [Google Scholar] [CrossRef] [PubMed]
- Gladkova, E.D.; Nechepurenko, I.V.; Bredikhin, R.A.; Chepanova, A.A.; Zakharenko, A.L.; Luzina, O.A.; Ilina, E.S.; Dyrkheeva, N.S.; Mamontova, E.M.; Anarbaev, R.O.; et al. The First Berberine-Based Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), an Important DNA Repair Enzyme. Int. J. Mol. Sci. 2020, 21, 7162. [Google Scholar] [CrossRef] [PubMed]
- Khomenko, T.M.; Zakharenko, A.L.; Chepanova, A.A.; Ilina, E.S.; Zakharova, O.D.; Kaledin, V.I.; Nikolin, V.P.; Popova, N.A.; Korchagina, D.V.; Reynisson, J.; et al. Promising New Inhibitors of Tyrosyl-DNA Phosphodiesterase I (Tdp 1) Combining 4-Arylcoumarin and Monoterpenoid Moieties as Components of Complex Antitumor Therapy. Int. J. Mol. Sci. 2020, 21, 126. [Google Scholar] [CrossRef] [PubMed]
- Dyrkheeva, N.S.; Filimonov, A.S.; Luzina, O.A.; Orlova, K.A.; Chernyshova, I.A.; Kornienko, T.E.; Malakhova, A.A.; Medvedev, S.P.; Zakharenko, A.L.; Ilina, E.S.; et al. New Hybrid Compounds Combining Fragments of Usnic Acid and Thioether Are Inhibitors of Human Enzymes TDP1, TDP2 and PARP1. Int. J. Mol. Sci. 2021, 22, 11336. [Google Scholar] [CrossRef] [PubMed]
- Duan, M.; Ulibarri, J.; Liu, K.J.; Mao, P. Role of Nucleotide Excision Repair in Cisplatin Resistance. Int. J. Mol. Sci. 2020, 21, 9248. [Google Scholar] [CrossRef] [PubMed]
- Fidrus, E.; Hegedűs, C.; Janka, E.A.; Paragh, G.; Emri, G.; Remenyik, É. Inhibitors of Nucleotide Excision Repair Decrease UVB-Induced Mutagenesis—An In Vitro Study. Int. J. Mol. Sci. 2021, 22, 1638. [Google Scholar] [CrossRef] [PubMed]
- Boichuk, S.; Bikinieva, F.; Nurgatina, I.; Dunaev, P.; Valeeva, E.; Aukhadieva, A.; Sabirov, A.; Galembikova, A. Inhibition of AKT-Signaling Sensitizes Soft Tissue Sarcomas (STS) and Gastrointestinal Stromal Tumors (GIST) to Doxorubicin via Targeting of Homology-Mediated DNA Repair. Int. J. Mol. Sci. 2020, 21, 8842. [Google Scholar] [CrossRef] [PubMed]
- Mechetin, G.V.; Endutkin, A.V.; Diatlova, E.A.; Zharkov, D.O. Inhibitors of DNA Glycosylases as Prospective Drugs. Int. J. Mol. Sci. 2020, 21, 3118. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Volcho, K.P.; Lavrik, O.I. Inhibition of DNA Repair Enzymes as a Valuable Pharmaceutical Approach. Int. J. Mol. Sci. 2023, 24, 7954. https://doi.org/10.3390/ijms24097954
Volcho KP, Lavrik OI. Inhibition of DNA Repair Enzymes as a Valuable Pharmaceutical Approach. International Journal of Molecular Sciences. 2023; 24(9):7954. https://doi.org/10.3390/ijms24097954
Chicago/Turabian StyleVolcho, Konstantin P., and Olga I. Lavrik. 2023. "Inhibition of DNA Repair Enzymes as a Valuable Pharmaceutical Approach" International Journal of Molecular Sciences 24, no. 9: 7954. https://doi.org/10.3390/ijms24097954